Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

The management of patients with myelodysplastic syndrome (MDS) refractory to hypomethylating agents (HMAs) remains a challenge with few reliably effective treatments. Preclinical studies have shown that the inhibition of the nuclear export protein XPO1 causes nuclear accumulation of p53 and disrupti...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yunshuo Xiao, Kun Yang, Qiuying Huang, Changqing Wei, Manlv Wei, Zhili Geng, Hui Wu, Tianhong Zhou, Xialoin Yin, Yali Zhou
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-12-01
Edice:	Frontiers in Oncology
Témata:	selinexor venetoclax hypomethylating agents myelodysplastic syndrome acute myeloid leukemia
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1477697/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!